<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1182">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365127</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000611</org_study_id>
    <nct_id>NCT04365127</nct_id>
  </id_info>
  <brief_title>Progesterone for the Treatment of COVID-19 in Hospitalized Men</brief_title>
  <official_title>A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara Ghandehari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and efficacy of progesterone for treatment of
      COVID-19 in hospitalized men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hospitalized men with COVID-19 who meet the eligibility criteria will be informed about study
      and the potential risks. All the patients giving written informed consent will be randomized
      in 1:1 ratio to progesterone (100 mg SQ twice daily) plus standard of care or standard of
      care alone.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">April 17, 2021</completion_date>
  <primary_completion_date type="Actual">August 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in clinical status of subjects at Day 7 based on the following 7-point ordinal scale</measure>
    <time_frame>7 days</time_frame>
    <description>Change in clinical status of subjects at Day 7 based on the following 7-point ordinal scale
Death
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
Hospitalized, on high flow oxygen devices
Hospitalized, requiring supplemental oxygen
Hospitalized, not requiring supplemental oxygen
Not hospitalized, limitation on activities
Not hospitalized, no limitations on activities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status of subjects assessed daily while hospitalized and on Day 15</measure>
    <time_frame>29 days</time_frame>
    <description>Change in clinical status of subjects daily while hospitalized and at Day 15 based on the following 7-point ordinal scale
Death
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
Hospitalized, on high flow oxygen devices
Hospitalized, requiring supplemental oxygen
Hospitalized, not requiring supplemental oxygen
Not hospitalized, limitation on activities
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen, mechanical ventilation (if applicable), and hospitalization</measure>
    <time_frame>15 days</time_frame>
    <description>The length of time that the subjects require supplemental oxygen.
The length of time that the subjects require mechanical ventilation (if applicable).
The length of time that the subjects remain in the hospital.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>COVID-19</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Progesterone plus SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone 100 mg will be administered subcutaneously twice daily for 5 days in addition to institutional standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will receive institutional standard of care only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone 100 MG</intervention_name>
    <description>Subcutaneous administration twice daily</description>
    <arm_group_label>Progesterone plus SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Laboratory-confirmed COVID-19 with in 72 hours prior to randomization

          2. Respiratory symptoms or abnormal lung exam or abnormal chest imaging AND oxygen
             saturation â‰¤94% on room air, or requiring supplemental oxygen less than 50% high flow

          3. Understands and agrees to comply with planned study procedures

          4. Agrees to the collection of venous blood per protocol

          5. Must agree to be placed on prophylactic dose of anticoagulation for prevention of deep
             venous thrombosis (DVT) while hospitalized

        Exclusion Criteria:

          1. ALT or AST &gt;5 times the upper limit of normal

          2. History of blood clots

          3. History of breast cancer

          4. Allergy to progesterone or betacyclodextrin

          5. Use of supplemental oxygen prior to hospital admission

          6. Requiring higher than 50% supplemental oxygen by high flow nasal cannula or mechanical
             ventilation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Ghandehari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hall OJ, Klein SL. Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites. Mucosal Immunol. 2017 Sep;10(5):1097-1107. doi: 10.1038/mi.2017.35. Epub 2017 Apr 12. Review.</citation>
    <PMID>28401937</PMID>
  </reference>
  <reference>
    <citation>Menzies FM, Henriquez FL, Alexander J, Roberts CW. Selective inhibition and augmentation of alternative macrophage activation by progesterone. Immunology. 2011 Nov;134(3):281-91. doi: 10.1111/j.1365-2567.2011.03488.x.</citation>
    <PMID>21977998</PMID>
  </reference>
  <reference>
    <citation>Jones LA, Anthony JP, Henriquez FL, Lyons RE, Nickdel MB, Carter KC, Alexander J, Roberts CW. Toll-like receptor-4-mediated macrophage activation is differentially regulated by progesterone via the glucocorticoid and progesterone receptors. Immunology. 2008 Sep;125(1):59-69. doi: 10.1111/j.1365-2567.2008.02820.x. Epub 2008 Mar 28.</citation>
    <PMID>18373668</PMID>
  </reference>
  <reference>
    <citation>Hall OJ, Limjunyawong N, Vermillion MS, Robinson DP, Wohlgemuth N, Pekosz A, Mitzner W, Klein SL. Progesterone-Based Therapy Protects Against Influenza by Promoting Lung Repair and Recovery in Females. PLoS Pathog. 2016 Sep 15;12(9):e1005840. doi: 10.1371/journal.ppat.1005840. eCollection 2016 Sep.</citation>
    <PMID>27631986</PMID>
  </reference>
  <reference>
    <citation>Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K, Ring L, Landau R, Purisch S, Friedman AM, Fuchs K, Sutton D, Andrikopoulou M, Rupley D, Sheen JJ, Aubey J, Zork N, Moroz L, Mourad M, Wapner R, Simpson LL, D'Alton ME, Goffman D. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM. 2020 May;2(2):100118. doi: 10.1016/j.ajogmf.2020.100118. Epub 2020 Apr 9.</citation>
    <PMID>32292903</PMID>
  </reference>
  <reference>
    <citation>Cometti B. Pharmaceutical and clinical development of a novel progesterone formulation. Acta Obstet Gynecol Scand. 2015 Nov;94 Suppl 161:28-37. doi: 10.1111/aogs.12765. Review.</citation>
    <PMID>26342177</PMID>
  </reference>
  <reference>
    <citation>Doblinger J, Cometti B, Trevisan S, Griesinger G. Subcutaneous Progesterone Is Effective and Safe for Luteal Phase Support in IVF: An Individual Patient Data Meta-Analysis of the Phase III Trials. PLoS One. 2016 Mar 18;11(3):e0151388. doi: 10.1371/journal.pone.0151388. eCollection 2016.</citation>
    <PMID>26991890</PMID>
  </reference>
  <reference>
    <citation>Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091. Erratum in: BMJ. 2020 Mar 31;368:m1295.</citation>
    <PMID>32217556</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Sara Ghandehari</investigator_full_name>
    <investigator_title>Attending Physician, Internal Medicine/Pulmonary Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

